Bodyport Inc.

Bodyport Inc. is a biomarker-guided digital therapeutics company specializing in remote monitoring solutions for complex chronic conditions, particularly heart failure. The company's FDA-cleared Bodyport Cardiac Scale (Fluiditi™) is a non-invasive, at-home device that measures hemodynamic biomarkers—including heart function and fluid status—through advanced sensors embedded in a bathroom scale. Patients simply step on the device for under 30 seconds, and data transmits via cellular connection to care teams within minutes. The proprietary Congestion Index algorithm combines multiple hemodynamic biomarkers into a composite metric for early detection of worsening heart failure, demonstrating superior performance over traditional weight-based monitoring in clinical validation. Bodyport's integrated care platform combines a clinical portal with a patient app, delivering actionable insights for timely clinician interventions. The system supports RPM billing, integrates via API with leading EHRs, and maintains HIPAA compliance and SOC 2 certification. The company partners with major health systems including Geisinger, Stanford, Duke, and Brigham & Women's Hospital, backed by peer-reviewed clinical evidence published in leading medical journals.